{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:20:46Z","timestamp":1778664046617,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cardiotoxicity presenting as cardiomyopathy is a common side effect in cancer treatment especially with anthracyclines. The role of genetic predisposition is still being investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>Four unrelated patients with a familial burden for cardiac disease, who developed cardiomyopathy after anthracycline treatment are presented. Case 1 received chemotherapy for breast cancer and developed a dilated left ventricle just after treatment. Her father had died unexpectedly while being screened for heart transplant. Case 2 was known with a family history of sudden cardiac death prior to her breast cancer diagnosis. She received anthracycline-containing chemotherapy treatment twice in 5 years due to recurrence of breast cancer. During that period, two brothers developed a cardiomyopathy. Eighteen years later, a genetic predisposition for cardiomyopathy was ascertained and at screening an asymptomatic non-ischaemic cardiomyopathy was established. Case 3 was diagnosed with a dilated cardiomyopathy 1 year after chemotherapy treatment for breast cancer. Her mother had developed a dilated cardiomyopathy several years before. Case 4 received chemotherapy treatment for Non-Hodgkin\u2019s lymphoma and developed dilated cardiomyopathy 1 year later. His brother died from congestive heart failure which he developed after chemotherapy for Non-Hodgkin\u2019s lymphoma and a grandmother had died suddenly during child delivery. In all four cases, genetic screening showed (likely) pathogenic variants in cardiomyopathy-associated genes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Current guidelines recommend cardiac evaluation in cancer patients receiving chemotherapy based on the presence of cardiovascular risk factors at the start of treatment. This series emphasizes the importance of including a thorough family history in this process.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytab333","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T14:52:03Z","timestamp":1631717523000},"source":"Crossref","is-referenced-by-count":7,"title":["Case series, chemotherapy-induced cardiomyopathy: mind the family history!"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-1030","authenticated-orcid":false,"given":"Setareh","family":"Moghadasi","sequence":"first","affiliation":[{"name":"Department of Clinical Genetics, LUMC, Postbus 9600 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rienke","family":"Fijn","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, LUMC, Postbus 9600 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia L M A","family":"Beeres","sequence":"additional","affiliation":[{"name":"Department of Cardiology, LUMC, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hennie","family":"Bikker","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Laboratorium Genoomdiagnostiek, AmsterdamUMC, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan D H","family":"Jongbloed","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Groningen, UMCG, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djike","family":"Josephus Jitta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, HMC, The Hague, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-1903","authenticated-orcid":false,"given":"Judith R","family":"Kroep","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, LUMC, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald H","family":"Lekanne Deprez","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Laboratorium Genoomdiagnostiek, AmsterdamUMC, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne J","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Groningen, UMCG, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00eblle J M","family":"de Vreede","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine- Hematology, HMC, The Hague, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1831-6698","authenticated-orcid":false,"given":"M Louisa","family":"Antoni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, LUMC, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Q C M","family":"Barge-Schaapveld","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, LUMC, Postbus 9600 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"2021102306420997700_ytab333-B1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrcardio.2015.133","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2021102306420997700_ytab333-B2","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2021102306420997700_ytab333-B3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","article-title":"Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients","volume":"11","author":"Henry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2021102306420997700_ytab333-B4","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021102306420997700_ytab333-B5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"2021102306420997700_ytab333-B6","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"2021102306420997700_ytab333-B7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"2021102306420997700_ytab333-B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2021102306420997700_ytab333-B9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2021102306420997700_ytab333-B10","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1097\/MJT.0000000000000453","article-title":"Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer","volume":"24","author":"Mihalcea","year":"2017","journal-title":"Am J Ther"},{"key":"2021102306420997700_ytab333-B11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.maturitas.2016.06.012","article-title":"Cardiovascular risk of BRCA1\/2 mutation carriers: a review","volume":"91","author":"van Westerop","year":"2016","journal-title":"Maturitas"},{"key":"2021102306420997700_ytab333-B12","doi-asserted-by":"crossref","first-page":"100421","DOI":"10.1016\/j.cpcardiol.2019.04.001","article-title":"Effects of breast cancer genes 1 and 2 on cardiovascular diseases","volume":"46","author":"Zhou","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"2021102306420997700_ytab333-B13","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/annonc\/mdr272","article-title":"Anthracycline-induced cardiomyopathy in siblings with early breast cancer","volume":"22","author":"Young","year":"2011","journal-title":"Ann Oncol"},{"key":"2021102306420997700_ytab333-B14","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/eurjhf\/hfq175","article-title":"Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?","volume":"12","author":"van den Berg","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2021102306420997700_ytab333-B15","doi-asserted-by":"crossref","first-page":"e537-8","DOI":"10.1200\/JCO.2011.34.8052","article-title":"Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy","volume":"29","author":"Shipman","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021102306420997700_ytab333-B16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cardfail.2017.03.003","article-title":"Truncating titin (TTN) variants in chemotherapy-induced cardiomyopathy","volume":"23","author":"Linschoten","year":"2017","journal-title":"J Card Fail"},{"key":"2021102306420997700_ytab333-B17","doi-asserted-by":"crossref","first-page":"e000116","DOI":"10.1136\/openhrt-2014-000116","article-title":"Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy","volume":"1","author":"Wasielewski","year":"2014","journal-title":"Open Heart"},{"key":"2021102306420997700_ytab333-B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"2021102306420997700_ytab333-B19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12471-017-1037-5","article-title":"A Dutch MYH7 founder mutation, p.(Asn1918Lys), is associated with early onset cardiomyopathy and congenital heart defects","volume":"25","author":"van der Linde","year":"2017","journal-title":"Neth Heart J"},{"key":"2021102306420997700_ytab333-B20","author":"Farmacotherapeutisch Kompas"},{"key":"2021102306420997700_ytab333-B21","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1093\/eurheartj\/ehu050","article-title":"Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy","volume":"35","author":"van Spaendonck-Zwarts","year":"2014","journal-title":"Eur Heart J"},{"key":"2021102306420997700_ytab333-B22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1505517","article-title":"Shared genetic predisposition in peripartum and dilated cardiomyopathies","volume":"374","author":"Ware","year":"2016","journal-title":"N Engl J Med"},{"key":"2021102306420997700_ytab333-B23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/CIRCRESAHA.119.313577","article-title":"Anthracycline and peripartum cardiomyopathies","volume":"124","author":"Cowgill","year":"2019","journal-title":"Circ Res"},{"key":"2021102306420997700_ytab333-B24","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"2021102306420997700_ytab333-B25","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2021102306420997700_ytab333-B26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"2021102306420997700_ytab333-B27","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"The Lancet"},{"key":"2021102306420997700_ytab333-B28","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytab333\/40392123\/ytab333.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/10\/ytab333\/40828209\/ytab333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/10\/ytab333\/40828209\/ytab333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T06:42:50Z","timestamp":1634971370000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytab333\/6370699"}},"subtitle":[],"editor":[{"given":"Diego","family":"Araiza-Garaygordobil","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Edin","family":"Begic","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Rafael","family":"Vidal-Perez","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Kajaluxy","family":"Ananthan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Anthony Paulo","family":"Sunjaya","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytab333","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,9,15]]},"article-number":"ytab333"}}